Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice

• Main Authors: Susanna Canali (Author), Alexander W. Fischer (Author), Mychael Nguyen (Author), Karl Anderson (Author), Lorna Wu (Author), Anne-Renee Graham (Author), Chiaowen Joyce Hsiao (Author), Chinmayi Bankar (Author), Nancy Dussault (Author), Veronica Ritchie (Author), Meagan Goodridge (Author), Todd Sparrow (Author), Allison Pannoni (Author), Sze-Wah Tse (Author), Vivienne Woo (Author), Kaitlin Klovdahl (Author), Jared Iacovelli (Author), Eric Huang (Author)
• Format: Book
• Published: Elsevier, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Interleukin (IL)-22 is a potential therapeutic protein for the treatment of metabolic diseases such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease due to its involvement in multiple cellular pathways and observed hepatoprotective effects. The sho...